Author:

CHDS welcomes Tai Dinger and Andrea Luviano to the PhD Program in Health Policy Decision Science track beginning Fall 2021. Dinger graduated from

CHDS affiliated faculty Jennifer Yeh and colleagues found that population-based genetic testing of newborns may reduce mortality associated with pediatric cancers and could be cost-effective as sequencing

Eyal Zimlichman, Sheba Medical Center’s Chief Medical Officer and Chief Innovation Officer, discussed innovations to address the COVID-19 pandemic at the May, 2021 CHDS seminar. Zimlichman presented

The “efficiency” of a program depends on how the benefits and costs are distributed in a population and on the units in which benefits and costs are measured, the so-called “numeraire.” This

Dr. Osondu Ogbuoji, Assistant Research Professor at the Duke Global Health Institute and Deputy Director at the Duke Center for Policy Impact in Global Health, presented research on a pooled-funding

CHDS’ affiliated faculty Myriam Hunink directs the Netherlands Institute for Health Sciences (NIHES), an international academic research institute that is part of the Erasmus University

The COVID-19 crisis has focused unprecedented attention on the use of benefit-cost analysis and approaches for valuing mortality risk reductions, commonly referred to as the

The Society for Risk Analysis recently featured a webinar, “Valuing Statistical Lives: Concepts, Current Practices, and Challenges,” led by CHDS researcher Lisa A. Robinson.

CHDS faculty Lisa A. Robinson and James K. Hammitt, and research staff Lucy O’Keeffe, recently published “Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis.”

The CHDS Media Hub team continues its ongoing mission to improve multi-modal pedagogy across the Harvard Chan School through a new partnership between Media Hub Director Jacob Waxman